Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Expanded Indication For Edwards’ Sapien 3 Squarely In Sight

This article was originally published in Clinica

Executive Summary

Edwards Lifesciences is on track to earn an expanded indication for its Sapien 3 transcatheter aortic valve replacement (TAVR) system – possibly earlier than expected – as the Sapien 3 observational study shows that patients deemed to be at intermediate risk for surgical complications may have better one-year outcomes with the TAVR system than surgical valve replacement.

Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT103325

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel